Well, I for one, am not happy about the sale of ExypnoTech.

I will miss the opportunity to travel to Germany to see this past branch of our business. Michael Kober and Bernhard Maier are good people and good business men.

Yes, though revenue had increased double digits, quarter over quarter, the margins were slim and the profits neglegible. It would have taken time to yield returns to NPCT/VYTC. But it was worth it.

Yet there was a sense of satisfaction in having the technology that I initially invested in, vindicated with strong sales.

This press release was rather shooting from the hip as it were. Darn the laws of Germany and the unworkable nature of a silent majority holder. I would have rather had 60% of the company than a quarter million bucks.

Well, as another poster stated, we can focus on BioAgra now. As a knowledgeable person pointed out to me a month ago, the profit potential of BioAgra far outweighs that of ExypnoTech.

I agree.

But I will miss ExypnoTech.

Heck, when VYTC is back up in price, I'll take a trip to Tagstar just for the heck of it and in my father's memory of the first U.S.A. investor to travel to see our past German enterprise.

Well, still very strong and long on VYTC. I do expect to see strong returns from BioAgra. May it be soon!

To all, may the New Year be blessed.

I am going back to the quiet recesses and listening but not speaking.

Kent